Your browser doesn't support javascript.
loading
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
Messerich, Nora-Medea; Uda, Narasimha Rao; Volken, Thomas; Cogliatti, Sergio; Lehmann, Thomas; Holbro, Andreas; Benz, Rudolf; Graf, Lukas; Gupta, Vikas; Jochum, Wolfram; Demmer, Izadora; Rao, Tata Nageswara; Silzle, Tobias.
Afiliación
  • Messerich NM; Department of Intensive Care, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Uda NR; Laboratory of Stem Cells and Cancer Biology, Department of Oncology and Hematology, Medical Research Center, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Volken T; ZHAW School of Health Sciences, Institute of Public Health, 8400 Winterthur, Switzerland.
  • Cogliatti S; Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Lehmann T; Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Holbro A; Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Benz R; Division of Hematology, University Hospital of Basel, University of Basel, 4001 Basel, Switzerland.
  • Graf L; Division of Hematology and Oncology, Spital Thurgau AG, 8569 Muensterlingen, Switzerland.
  • Gupta V; Centre for Laboratory Medicine, 9001 St. Gallen, Switzerland.
  • Jochum W; Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5S 1A1, Canada.
  • Demmer I; Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Rao TN; Institute of Pathology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
  • Silzle T; Laboratory of Stem Cells and Cancer Biology, Department of Oncology and Hematology, Medical Research Center, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Cancers (Basel) ; 15(5)2023 Feb 25.
Article en En | MEDLINE | ID: mdl-36900271
In myelofibrosis, the C-reactive protein (CRP)/albumin ratio (CAR) and the Glasgow Prognostic Score (GPS) add prognostic information independently of the Dynamic International Prognostic Scoring System (DIPSS). Their prognostic impact, if molecular aberrations are considered, is currently unknown. We performed a retrospective chart review of 108 MF patients (prefibrotic MF n = 30; primary MF n = 56; secondary MF n = 22; median follow-up 42 months). In MF, both a CAR > 0.347 and a GPS > 0 were associated with a shorter median overall survival (21 [95% CI 0-62] vs. 80 months [95% CI 57-103], p < 0.001 and 32 [95% CI 1-63] vs. 89 months [95% CI 65-113], p < 0.001). Both parameters retained their prognostic value after inclusion into a bivariate Cox regression model together with the dichotomized Mutation-Enhanced International Prognostic Scoring System (MIPSS)-70: CAR > 0.374 HR 3.53 [95% CI 1.36-9.17], p = 0.0095 and GPS > 0 HR 4.63 [95% CI 1.76-12.1], p = 0.0019. An analysis of serum samples from an independent cohort revealed a correlation of CRP with levels of interleukin-1ß and albumin with TNF-α, and demonstrated that CRP was correlated to the variant allele frequency of the driver mutation, but not albumin. Albumin and CRP as parameters readily available in clinical routine at low costs deserve further evaluation as prognostic markers in MF, ideally by analyzing data from prospective and multi-institutional registries. Since both albumin and CRP levels reflect different aspects of MF-associated inflammation and metabolic changes, our study further highlights that combining both parameters seems potentially useful to improve prognostication in MF.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Suiza